GENELUX Corp financial data

Symbol
GNLX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2625 Townsgate Road, Suite 230, Westlake Village, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 452 % +260%
Debt-to-equity 31.1 % -94.3%
Return On Equity -105 % +86.2%
Return On Assets -80.2 % +31.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.5M shares +29.3%
Common Stock, Shares, Outstanding 34.5M shares +29.6%
Entity Public Float 671M USD
Common Stock, Value, Issued 35K USD +29.6%
Weighted Average Number of Shares Outstanding, Basic 34.5M shares +31.8%
Weighted Average Number of Shares Outstanding, Diluted 34.5M shares +31.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 8K USD -95.3%
Research and Development Expense 16.6M USD +50.2%
General and Administrative Expense 12.3M USD +30.8%
Operating Income (Loss) -28.9M USD -42.9%
Nonoperating Income (Expense) 1.29M USD
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -5.35M USD -189%
Net Income (Loss) Attributable to Parent -27.7M USD -10.5%
Earnings Per Share, Basic -0.9 USD/shares +54.1%
Earnings Per Share, Diluted -0.9 USD/shares +5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.1M USD -79.6%
Cash, Cash Equivalents, and Short-term Investments 35.1M USD
Assets, Current 36M USD +15.4%
Property, Plant and Equipment, Net 1.28M USD +25%
Operating Lease, Right-of-Use Asset 1.93M USD +8.49%
Other Assets, Noncurrent 92K USD 0%
Assets 40.3M USD +18.2%
Employee-related Liabilities, Current 2.68M USD
Liabilities, Current 5.56M USD -36.6%
Operating Lease, Liability, Noncurrent 1.62M USD +26%
Liabilities 7.18M USD -28.5%
Accumulated Other Comprehensive Income (Loss), Net of Tax 124K USD +6100%
Retained Earnings (Accumulated Deficit) -242M USD -12.9%
Stockholders' Equity Attributable to Parent 33.1M USD +37.7%
Liabilities and Equity 40.3M USD +18.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.35M USD +5.14%
Net Cash Provided by (Used in) Financing Activities 688K USD -95.3%
Net Cash Provided by (Used in) Investing Activities -1.69M USD -1451%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 34.5M shares +29.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -5.36M USD -154%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.1M USD -79.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 50K USD -65.8%
Deferred Tax Assets, Valuation Allowance 58.9M USD +17.5%
Deferred Tax Assets, Gross 58.9M USD +17.5%
Operating Lease, Liability 2.04M USD +9.86%
Depreciation 84K USD -38.2%
Payments to Acquire Property, Plant, and Equipment 30K USD -72.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27.5M USD -18.5%
Property, Plant and Equipment, Gross 4.91M USD +12.1%
Operating Lease, Liability, Current 415K USD -26.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 330K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 653K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 362K USD
Deferred Tax Assets, Operating Loss Carryforwards 22.3K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares
Lessee, Operating Lease, Liability, to be Paid, Year Four 331K USD
Operating Lease, Payments 148K USD +29.8%
Additional Paid in Capital 276M USD +15.3%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 62.8M USD +18.3%
Share-based Payment Arrangement, Expense 1.49M USD +556%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares